HPV and HIV coinfection: A complex interaction resulting in epidemiological, clinical and therapeutic implications

Future Virology

Volumn 8, Issue 9, 2013, Pages 903-915

  Konopnicki, Deborah ^a   De Wit, Stephane ^a   Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

anal cancer; cervical cancer; dysplasia; HAART; HIV; HPV; HPV vaccine; men; MSM; women

Indexed keywords

ANTIRETROVIRUS AGENT; INTERFERON; LOPINAVIR; PLACEBO; WART VIRUS VACCINE;

CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INJECTION SITE REACTION; MIXED INFECTION; NONHUMAN; PANDEMIC; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; VACCINATION; WART VIRUS;

EID: 84883242017     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.69     Document Type: Review

References (82)

1. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV 1 acquisition and transmission: A review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35(5), 435-445 (2004
2. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: Systematic review and meta-analysis of longitudinal studies. AIDS 20(1), 73-83 (2006
3. Romanowski B, Myziuk LN, Walmsley SL et al. Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. Sex. Transm. Dis. 36(3), 165-169 (2009
4. Veldhuijzen NJ, Snijders PJ, Reiss P, Meijer CJ, van de Wijgert JH. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect. Dis. 10(12), 862-874 (2010
5. Muñoz N, Bosch FX, de Sanjosé S et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010
7. Tugizov S, Herrera R, Veluppillai P, Greenspan D, Palefsky J. HIV-facilitated paracellular penetration of HPV into mucosal epithelium. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22-27 July 2012
8. Vernon SD, Hart CE, Reeves WC, Icenogle JP. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res. 27(2), 133-145 (1993
9. Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G. Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 36(2), 57-64 (1993
10. Dolei A, Curreli S, Marongiu P et al. Human immunodeficiency virus infection in vitro activates naturally integrated human papillomavirus type 18 and induces synthesis of the L1 capsid protein. J. Gen. Virol. 80, 2937-2944 (1999
11. Bélec L, Gherardi R, Payan C et al. Proinflammatory cytokine expression in cervicovaginal secretions of normal and HIV-infected women. Cytokine 7(6), 568-574 (1995
12. Gonçalves MA, Soares EG, Donadi EA. The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity. Infect. Agent Cancer 4, 11 (2009
13. Ahdieh L, Klein R, Burk R et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J. Infect. Dis. 184, 682-690 (2001
14. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia and cancer in the era of highly active antiretroviral therapy. Curr. Opin. Oncol. 15, 382-388 (2003
15. Strickler HD, Burk RD, Fazzari M et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J. Natl Cancer Inst. 97(8), 577-586 (2005
16. Konopnicki D, Manigart Y, Gilles C et al. High-risk human papillomavirus infection in HIV-positive African women living in Europe. J. Int. AIDS Soc. 16, 18023 (2013
17. Muñoz N, Mendez F, Posso H et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J. Infect. Dis. 190(12), 2077-2087 (2004
18. Franco E, Villa L, Sobrinho P et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J. Infect. Dis. 180, 1415-1423 (1999
19. Mbulawa Z, Marais D, Johnson L, Coetzee D, Williamson A. Impact of human immunodeficiency virus on the natural history of human papillomavirus genital infection in South African men and women. J. Infect. Dis. 206(1), 15-27 (2012
20. Luque A, Demeter L, Reichman R. Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV 1) RNA plasma level among women with HIV-1 infection. J. Infect. Dis. 179(6), 1405-1409 (1999
21. Swindells S, Evans S, Zackin R et al.; AIDS Clinical Trial Group 722 Study TeAm. Predictive value of HIV-1 viral load on risk for opportunistic infection. J. Acquir. Immune Defic. Syndr. 30(2), 154-158 (2002
22. Mocroft A, Reiss P, Kirk O et al.; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin. Infect. Dis. 51(5), 611-619 (2010
23. Crowley-Nowick P, Ellenberg J, Vermund S, Douglas S, Holland C, Moscicki A. Cytokine profile in genital tract secretions from female adolescents: Impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J. Infect. Dis. 181(3), 939-945 (2000
24. Moscicki A, Ellenberg J, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: Risk factors and differences, by phylogenetic type. J. Infect. Dis. 190(1), 37-45 (2004
25. Nowak R, Gravitt P, Morrison C et al. Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe. J. Infect. Dis. 203(8), 1182-1191 (2011
26. Zhang Z, Wietgrefe S, Li Q et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl Acad. Sci. USA 101(15), 5640-5645 (2004
27. Cheng SH, Chu FY, Lin YS, Hsueh YM. Influence of age and CD4+ T cell counts on the prevalence of genital human papillomavirus infection among HIV-seropositive men who have sex with men in Taiwan. J. Med. Virol. 84(12), 1876-1883 (2012
28. Read TR, Hocking JS, Vodstrcil LA et al. Oral human papillomavirus in men having sex with men: Risk-factors and sampling. PLoS ONE 7(11), e49324 (2012
29. Amornthatree K, Sriplung H, Mitarnun W, Nittayananta W. Impacts of HIV infection and long-term use of antiretroviral therapy on the prevalence of oral human papillomavirus type 16. J. Oral Pathol. Med. 41(4), 309-314 (2012
30. Massad LS, Riester KA, Anastos KM et al. Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women's Interagency HIV Study Group. J. Acquir. Immune Defic. Syndr. 21(1), 33-41 (1999
31. Ellerbrock TV, Chiasson MA, Bush TJ et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283(8), 1031-1037 (2000
32. Coleman N, Birley H, Renton A et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102(6), 768-774 (1994
33. Gilles C, Manigart Y, Konopnicki D, Barlow P, Rozenberg S. Management and outcome of cervical intraepithelial neoplasia lesions: A study of matched cases according to HIV status. Gynecol. Oncol. 96(1), 112-118 (2005
34. Machalek DA, Poynten M, Jin F et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis. Lancet Oncol. 13(5), 487-500 (2012
35. Palefsky JM, Holly EA, Hogeboom CJ et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17(4), 314-319 (1998
36. Chaturvedi A, Madeleine M, Biggar R, Engels E. Risk of human papillomavirus-associated cancers among persons with AIDS. J. Natl Cancer Inst. 101(16), 1120-1130 (2009
37. Houlihan CF, Larke NL, Watson-Jones D et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 26(17), 2211-2222 (2012
38. Chin-Hong PV, Husnik M, Cranston RD et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS 23(9), 1135-1142 (2009
39. Laga M, Manoka A, Kivuvu M et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 7(1), 95-102 (1993
40. Laurson J, Khan S, Chung R, Cross K, Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 31(5), 918-926 (2010
41. Averbach SH, Gravitt PE, Nowak RG et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 24(7), 1035-1042 (2010
42. Tobian AA, Grabowski MK, Kigozi G et al. Human papillomavirus clearance among males is associated with HIV acquisition and increased dendritic cell density in the foreskin. J. Infect. Dis. 207(11), 1713-1722 (2013
43. Mbulawa ZZ, Coetzee D, Marais DJ et al. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J. Infect. Dis. 199(10), 1514-1524 (2009
44. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202(12), 1789-1799 (2010
45. Clifford GM, Gonçalves MA, Franceschi S; HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: A meta-analysis. AIDS 20(18), 2337-2344 (2006
46. Ndiaye C, Alemany L, Ndiaye N et al. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: Could HIV explain the differences? Trop. Med. Int. Health. 17(12), 1432-1440 (2012
47. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: Current evidence and directions for future research. Infect. Agent Cancer 5, 8 (2010
48. Shrestha S, Sudenga S, Smith J, Bachmann L, Wilson C, Kempf M. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect. Dis. 10, 295 (2010
49. Fife K, Wu J, Squires K, Watts D, Andersen J, Brown DR. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 51(3), 274-282 (2009
50. Minkoff H, Zhong Y, Burk R et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J. Infect. Dis. 201(5), 681-690 (2010
51. Konopnicki D, Manigart Y, Gilles C et al. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J. Infect. Dis. 207(11), 1723-1729 (2013
52. Blitz S, Baxter J, Raboud J et al.; Canadian Women's HIV Study Group. Evaluation of HIV and HAART on the natural history of HPV infection and cervical cytopathology in HIV-positive and high risk HIV-negative women. J. Infect. Dis. 208(3), 454-462 (2013
53. Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed. 78(1), 36-40 (2007
54. Adler DH, Kakinami L, Modisenyane T et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. AIDS 26(13), 1645-1652 (2012
55. Piketty C, Darragh TM, Da Costa M et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann. Intern. Med. 138(6), 453-459 (2003
56. Palefsky JM, Holly EA, Ralston ML et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J. Acquir. Immune Defic. Syndr. 28(5), 422-428 (2001
57. Piketty C, Darragh TM, Heard I et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex. Transm. Dis. 31(2), 96-99 (2004
58. Palefsky JM, Holly EA, Efirdc JT et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 19(13), 1407-1414 (2005
59. Piketty C, Cochand-Priollet B, Lanoy E et al.; Valparaiso Study Group. Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. AIDS 27(3), 401-406 (2013
60. de Pokomandy A, Rouleau D, Ghattas G et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin. Infect. Dis. 52(9), 1174-1181 (2011
61. van der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HA, van Doornum GJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex. Transm. Dis. 39(7), 495-500 (2012
62. Dal Maso L, Polesel J, Serraino D et al.; Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br. J. Cancer 100(5), 840-847 (2009
63. Palefsky JM. Antiretroviral therapy and anal cancer: The good, the bad, and the unknown. Sex. Transm. Dis. 39(7), 501-503 (2012
64. Silverberg MJ, Lau B, Justice AC et al.; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin. Infect. Dis. 54(7), 1026-1034 (2012
65. Bruyand M, Ryom L, Shepherd L et al.; D:A:D Study Group. Cancer risk and use of PI or NNRTI-based combination antiretroviral therapy(cART): The D:A:D study. Presented at: 20th Conference on Retroviruses and Opportunistic infections. Atlanta, GA, USA, 3-6 March 2013
66. Mbang P, Kowalkowski M, Chiao E. The impact of protease inhibitors on the incidence of HIV-associated squamous cell carcinoma of the anus. Presented at: 20th Conference on Retroviruses and Opportunistic infections. Atlanta, GA, USA, 3-6 March 2013
67. Wiesmann F, Eldering G, Braun P, Panstruga P, Ehret R, Knetcten H. Impact of protease inhibitor containing therapy on human papilloma virus coinfections in HIV-1 positive patients. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22-27 July 2012
68. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007
69. Paavonen J, Naud P, Salmerón J et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009
70. Kreimer AR, González P, Katki HA et al.; CVT Vaccine Group. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12(9), 862-870 (2011
71. Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364(5), 401-411 (2011
72. Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 365(17), 1576-1585 (2011
73. Levin M, Moscicki A, Song L et al. Safety and immunogenicity of a quadrivalent human papillomavirus (type 6, 11, 16 and 18) vaccine in HIV-infected children 7 to 12 years old. J. Acquir. Immune Defic. Syndr. 55(2), 197-204 (2010
74. Kahn J, Xu J, Kapogiannis B et al. Immunogenicity of the HPV-6, -11, -16, -18 vaccine in HIV-positive young women. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22-27 July 2012
75. Kojic E, Cespedes M, Umbleja T et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-positive women. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22-27 July 2012
76. Wilkin T, Lee JY, Lensing SY et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. Infect. Dis. 202(8), 1246-1253 (2010
77. Sahasrabuddhe VV, Castle PE, Follansbee S et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J. Infect. Dis. 207(3), 392-401 (2013
78. Serrano B, Alemany L, Tous S et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agent Cancer 7(1), 38 (2012
79. Tabrizi SN, Brotherton JM, Kaldor JM et al. Fall in human papillomavirus prevalence following a national vaccination progrAm. J. Infect. Dis. 206(11), 1645-1651 (2012
80. Ali H, Guy RJ, Wand H et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination progrAm. BMC Infect. Dis. 13, 140 (2013
81. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838-1847 (2009
82. Anderson JS, Hoy J, Hillman R et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J. Acquir. Immune Defic. Syndr. 52(3), 371-381 (2009